Clinical Studies The efficacy of TRESIBA administered once-daily either at the same time each day or at any time each day in patients with type 1 diabetes and used in combination with a mealtime insulin was evaluated in three randomized, open-label, treat-to-target, active-controlled trials in adults and one randomized, open-label, treat-to-target, active-controlled trial in pediatric patients 1 year of age and older
GHK-Cu ist ein natrlich vorkommendes Kupfertripeptid, das im Zusammenhang mit Haut, Kollagen, Haaren, Geweberegeneration und Alterungsprozessen wissenschaftliches Interesse weckt
Some patients may continue treatment, some may reduce dose, and some may transition off with close monitoring
Ranasinghe P, Jayawardena R, Gamage N, et al